Challenges on Induction of Broadly Neutralizing Antibodies for Optimization of HIV Vaccines Development and Vectored Immunoprophylaxis
Pankaj Kumar
University of Saskatchewan, Saskatoon, Canada.
DOI: 10.4236/jibtva.2013.21002   PDF    HTML   XML   6,841 Downloads   14,664 Views   Citations


Despite extensive research efforts, a preventive human immunodeficiency virus (HIV) vaccine remains one of the major challenges in the field of AIDS research. Experimental strategies which have been proven successful for other viral vaccines are not enough to tackle HIV-1 and new approaches to design effective preventive AIDS vaccines are of utmost importance. Due to enormous diversity among global circulating HIV strains, an effective HIV vaccine must elicit broadly protective antibodies based responses; therefore discovering new broadly neutralizing antibodies (bNAbs) against HIV has become major focus in HIV vaccine research. However further understanding of the viral targets of such antibodies and mechanisms of action of bNAbs is required for advancement of HIV vaccine research. This technical note discusses our current knowledge on the bNAbs and immunoprophylaxis using viral vectors with their relevance in designing of new candidates to HIV-1 vaccines.

Share and Cite:

P. Kumar, "Challenges on Induction of Broadly Neutralizing Antibodies for Optimization of HIV Vaccines Development and Vectored Immunoprophylaxis," Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol. 2 No. 1, 2013, pp. 9-13. doi: 10.4236/jibtva.2013.21002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. P. Buchbinder, D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. D. Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey and M. N. Robertson, “The Step Study Protocol Team. Efficacy Aassessment of a Cell-Mediated Immunity HIV-1 Vaccine (the Step Study): A Double-Blind, Randomised, Placebo-Controlled, Test-of-Concept Trial,” Lancet, Vol. 372, No. 9653, 2008, pp. 1881-1893. doi:10.1016/S0140-6736(08)61591-3
[2] M. J. McElrath , S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K.Carter , J. Hural, R. Akondy, S. P. Buchbinder, M. N. Robertson, D. V. Mehrotra, S. G. Self, L. Corey, J. W. Shiver and D. R. Casimiro, “Step Study Protocol Team. HIV-1 Vaccine- Induced Immunity in the Test-of-Concept Step Study: A Case—Cohort Analysis,” Lancet, Vol. 372, No. 9653, 2008, pp. 1894-1905. doi:10.1016/S0140-6736(08)61592-5
[3] J. Liu, K. L. O’Brien, D. M. Lynch, N. L.Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. T. Coffey, L. E. Grandpre, M. S. Seaman, G. Landucci, D. N. Forthal, D. C. Montefiori, A. Carville, K. G. Mansfield, M. J. Havenga, M. G. Pau, J. Goudsmit and D. H. Barouch, “Immune Control of an SIV Challenge by a T-Cell-Based Vaccine in Rhesus Monkeys,” Nature, Vol. 457, No. 7225, 2009, pp. 87-91. doi:10.1038/nature07469
[4] S. G. Hansen, C. Vieville, N. Whizin, L. Coyne-Johnson, D. C. Siess, D. D. Drummond, A. W. Legasse, M. K. Axthelm, K. Oswald, C. M.Trubey, M. Piatak Jr, J. D. Lifson, J. A. Nelson, M. A.Jarvis and L. J. Picker, “Effector Memory T Cell Responses Are Associated with Protection of Rhesus Monkeys from Mucosal Simian Immunodeficiency Virus Challenge,” Nature Medicine, Vol. 15, No. 3, 2009, pp. 293-299. doi:10.1038/nm.1935
[5] S. G. Hansen, J. C. Ford, M. S. Lewis, A. B Ventura, C. M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, A. W. Legasse, M. J. Chiuchiolo, C. L. Parks, M. K. Axthelm, J. A. Nelson, M. A. Jarvis, M. Piatak Jr, J. D. Lifson and L. J. Picker, “Profound Early Control of Highly Pathogenic SIV by an Effector Memory T-Cell Vaccine,” Nature, Vol. 473, No. 7348, 2011, pp. 523-527. doi:10.1038/nature10003
[6] L. Stamatatos, L. Morris, D. R. Burton and J. R. Mascola, “Neutralizing Antibodies Generated during Natural HIV-1 Infection: Good News for an HIV-1 Vaccine?” Nature Medicine, Vol. 15, No. 8, 2009, pp. 866-870.
[7] S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J. G.McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thong-charoen, M. L. Robb, N. L. Michael, P. Kunasol and J. H. Kim, “MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand,” The New England Journal of Medicine, Vol. 361, No. 23, 2009, pp. 2209-2220. doi:10.1056/NEJMoa0908492
[8] T. Zhou, I. Georgiev, X. Wu, Z. Y. Yang, K. Dai, A. Finzi, Y. D. Kwon, J. F. Scheid, W. Shi, L. Xu, Y. Yang, J. Zhu, M. C. Nussenzweig, J. Sodroski, L. Shapiro, G. J. Nabel, J. R. Mascola and P. D. Kwong, “Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01,” Science, Vol. 329, No. 5993, 2010, pp. 811-817. doi:10.1126/science.1192819
[9] X. Wu, Z. Y.Yang, Y. Li, C. M. Hogerkorp, W. R. Schief, M. S. Seaman, T. Zhou, S. D. Schmidt, L. Wu, L. Xu, N. S. Longo, K. McKee, S. O’Dell, M. K. Louder, D. L. Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P. D. Kwong, M. Roederer, R. T.Wyatt, G. J. Nabel and J. R. Mascola, “Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1,” Science, Vol. 329, No. 5993, 2010, pp. 856-561. doi:10.1126/science.1187659
[10] X. Wu, T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N. S. Longo, M. Louder, K. McKee, S. O’Dell, S. Perfetto, S. D. Schmidt, W. Shi, L. Wu, Y. Yang, Z. Y. Yang, Z. Yang, Z. Zhang, M. Bonsignori, J. A. Crump, S. H. Kapiga, N. E. Sam, B. F. Haynes, M. Simek, D. R. Burton, W. C. Koff, N. A. Doria-Rose, M. Connors, J. C. Mullikin, G. J. Nabel, M. Roederer, L. Shapiro, P. D. Kwong and J. R. Mascola, “Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing,” Science, Vol. 333, No. 6049, 2011, pp. 1593-1602. doi:10.1126/science.1207532
[11] J. F. Scheid, H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T. Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D. R. Burton, F. Pereyra, D. D. Ho, B. D. Walker, M. S. Seaman, P. J. Bjorkman, B. T. Chait and M. C. Nussenzweig, “Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding,” Science, Vol. 333, No. 6049, 2011, pp. 1633-1637. doi:10.1126/science.1207227
[12] L. M. Walker, S. K. Phogat, P. Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey and P. W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard and D. R. Burton, “Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target,” Science, Vol. 326, No. 5950, 2009, pp. 285-289. doi:10.1126/science.1178746
[13] L. M. Walker, M. Huber, K. J. Doores, E. Falkowska, R. Pejchal, J. P. Julien, S. K. Wang, A. Ramos, P. Y. Chan-Hui, M. Moyle, J. L. Mitcham, P. W. Hammond, O. A. Olsen, P. Phung, S. Fling, C. H. Wong, S. Phogat, T. Wrin and M. D. Simek, W. C. Koff, I. A. Wilson, D. R. Burton and P. Poignard, “Broad Neutralization Coverage of HIV by Multiple Highly Potent Antibodies,” Nature, Vol. 477, No. 7365, 2011, pp. 466-70. doi:10.1038/nature10373
[14] C. Sundling, M. N. Forsell, S. O’Dell, Y. Feng, B. Chakrabarti, S. S. Rao, K. Loré, J. R. Mascola, R. T. Wyatt, I. Douagi and G. B. Karlsson Hedestam Soluble HIV-1 Env Trimers in Adjuvant Elicit Potent and Diverse Functional B Cell Responses in Primates,” Journal of Experimental Medicine, Vol. 207, No. 9, 2010, pp. 2003-2017. doi:10.1084/jem.20100025
[15] J. M. Kovacs, J. P. Nkolola, H. Peng, A. Cheung, J. Perry, C. A. Miller, M. S. Seaman, D. H. Barouch and B. Chen, “HIV-1 Envelope Trimer Elicits More Potent Neutralizing Antibody Responses than Monomeric gp120,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 30, 2012, Article ID: 12111. doi:10.1073/pnas.1204533109
[16] B. K. Chakrabarti, M. Pancera, S. Phogat, S. O’Dell, K. McKee, J. Guenaga, J. Robinson, J. Mascola and R. T. Wyatt, “HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies,” AIDS Research and Human Retroviruses, Vol. 27, No. 8, 2011, pp. 877-887. doi:10.1089/aid.2010.0281
[17] M. A. Liu, “Gene-Based Passive Antibody Protection from HIV,” Nature Biotechnology, Vol. 30, No. 2, 2012, pp. 156-157. doi:10.1038/nbt.2114
[18] A. B. Balazs, J. Chen, C. M. Hong, D. S. Rao, L. Yang and D. Baltimore, “Antibody-Based Protection against HIV Infection by Vectored Immunoprophylaxis,” Nature, Vol. 481, No. 7379, 2011, pp. 81-84. doi:10.1038/nature10660
[19] S. L. Murphy, H. Li, F. Mingozzi, D. E. Sabatino, D. J. Hui, S. A. Edmonson and K. A. High, “Diverse IgG Subclass Responses to Adeno-Associated Virus Infection and Vector Administration,” Journal of Medical Virology, Vol. 81, No. 1, 2009, pp. 65-74. doi:10.1002/jmv.21360
[20] G. L. Rogers, A. T. Martino, G. V. Aslanidi, G. R. Jayandharan, A. Srivastava and R. W. Herzog, “Innate Immune Responses to AAV Vectors,” Frontiers in Microbiology, Vol. 2, 2011, p. 194.
[21] S. Ratto-Kim, J. R. Currier, J. H. Cox, J. L.Excler, A. Valencia-Micolta, D. Thelian, V. Lo, E. Sayeed, V. R. Polonis, P. L. Earl, B. Moss, M. L. Robb, N. L. Michael, J. H. Kim and M. A. Marovich, “Heterologous Prime- Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins than Homologous Regimens,” PLoS One, Vol. 7, No. 9, 2012, p. e45840. doi:10.1371/journal.pone.0045840
[22] S. A. Brown, S. L. Surman, R. Sealy, B. G. Jones, K. S. Slobod, K. Branum, T. D. Lockey, N. Howlett, P. Freiden, P. Flynn and J. L. Hurwitz, “Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials,” Viruses, 2010; Vol. 2, No. 2, pp. 435-467. doi:10.3390/v2020435
[23] C. Li, Z. Shen, X. Li, J. Bai, L. Zeng, M. Tian, Y. J. Song, M. Ye, S. Du, D. Ren, C. Liu, N. Zhu, D. Sun, Y. Li and N. Jin, “Protection against SHIV-KB9 Infection by Combining rDNa and rFPV Vaccines Based on HIV Multiepitope and P24 Protein in Chinese Rhesus Macaques,” Clinical and Developmental Immunology, Vol. 2012, 2012, Article ID: 958404.
[24] M. C. Keefer, J. Gilmour, P. Hayes, D. Gill, J. Kopycinski, H. Cheeseman, M. Cashin-Cox, M. Naarding, L. Clark, N. Fernandez, C. A. Bunce, C. M. Hay, S. Welsh, W. Komaroff, L. Hachaambwa, T. Tarragona-Fiol, E. Sayeed, D. Zachariah, J. Ackland, K. Loughran, B. Barin, E. Cormier, J. H. Cox, P. Fast and J. L. Excler, “A Phase Ⅰ Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults,” PLoS One, Vol. 7, No. 8, 2012, p. e41936. doi:10.1371/journal.pone.0041936
[25] T. W. Geisbert, M. Bailey, L. Hensley, C. Asiedu, J. Geisbert, D. Stanley, A. Honko, J. Johnson, S. Mulangu, M. G. Pau, J. Custers, J. Vellinga, J. Hendriks, P. Jahrling, M. Roederer, J. Goudsmit, R. Koup and N. J. Sullivan, “Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge,” Journal of Virology, Vol. 85, No. 10, 2011, pp. 4222-4233. doi:10.1128/JVI.02407-10
[26] N. L. Michael, “Rare Serotype Adenoviral Vectors for HIV Vaccine Development,” The Journal of Clinical Investigation, Vol. 122, No. 1, 2012, pp. 25-27. doi:10.1172/JCI60988
[27] J. D. Fuchs, C. Morgan, P. Bart, N. Kochar, N. Frahm, E. Swann, P. Gilbert, S. DeRosa, B. Graham, G. Nabel, H. Liao, B. Haynes and G. Tomaras, “DNA and Recombinant Adenovirus Serotype 35 and 5 Preventive HIV-1 Vaccines with Env a Inserts Elicit Cross-Clade Binding and V1V2 Antibodies,” Retrovirology, Vol. 9 No. S2, 2012, p. 136. doi:10.1186/1742-4690-9-S2-P136
[28] M. Rolland, P. T. Edlefsen, B. B. Larsen, S. Tovanabutra, E. Sanders-Buell, T. Hertz, A. C. deCamp, C. Carrico, S. Menis, C. A. Magaret, H. Ahmed, M. Juraska, L. Chen, P. Konopa, S. Nariya, J. N. Stoddard, K. Wong, H. Zhao, W. Deng, B. S. Maust, M. Bose, S. Howell, A. Bates, M. Lazzaro, A. O’Sullivan, E. Lei, A. Bradfield, G. Ibitamuno, V. Assawadarachai, R. J. O’Connell, M. S. de- Souza, S. Nitayaphan, S. Rerks-Ngarm, M. L. Robb, J. S. McLellan, I. Georgiev, P. D. Kwong, J. M. Carlson, N. L. Michael, W. R. Schief, P. B. Gilbert, J. I. Mullins and J. H. Kim, “Increased HIV-1 Vaccine Efficacy against Viruses with Genetic Signatures in Env V2,” Nature, Vol. 490, No. 7420, 2012, pp. 417-420. doi:10.1038/nature11519
[29] B. F. Haynes, P. B. Gilbert, M. J. McElrath, S. Zolla- Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, H. X. Liao, A. L. DeVico, G. K. Lewis, C. Williams, A. Pinter, Y. Fong, H. Janes, A. DeCamp, Y. Huang, M. Rao, E. Billings, N. Karasavvas, M. L. Robb, V. Ngauy, M. S. de Souza, R. Paris, G. Ferrari, R. T. Bailer, K. A. Soderberg, C. Andrews, P. W. Berman, N. Frahm, S. C. De Rosa, M. D. Alpert, N. L. Yates, X. Shen, R. A. Koup, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, S. Rerks-Ngarm, N. L. Michael and J. H. Kim, “Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy trial,” The New England Journal of Medicine, Vol. 366, No. 14, 2012, pp. 1275-1286. doi:10.1056/NEJMoa1113425

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.